| abstract |
The present disclosure relates to compounds and methods for treating conditions associated with fluid retention or salt overload, such as heart failure (particularly congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisomes Proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure also relates to compounds and methods for treating hypertension. The present disclosure also relates to compounds and methods for treating gastrointestinal disorders, including treating or alleviating pain associated with gastrointestinal disorders. |